Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | GPR4 | P46093 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207211 | 0.92 | BCHE (0.37) | BCHEACHEBACE1IRAK4MAP2K2 | |
| SCHEMBL6206922 | 0.92 | BCHE (0.37) | BCHEACHEBACE1MAP2K2MAP2K1 | |
| SCHEMBL6230497 | 0.89 | KCNH2 (0.38) | BCHEACHEBACE1MAP2K2MAP2K1 | |
| SCHEMBL6206805 | 0.89 | BCHE (0.39) | BCHEACHEBACE1MAPT | |
| SCHEMBL6208348 | 0.88 | EEF2K (0.37) | BCHEACHEBACE1MAPTTSHR | |
| SCHEMBL6403567 | 0.87 | BCHE (0.43) | BCHEACHEBACE1MAPT | |
| SCHEMBL6205424 | 0.86 | ACHE (0.56) | BCHEACHEBACE1MAPT | |
| SCHEMBL6208052 | 0.85 | HRH3 (0.34) | BCHEACHEBACE1 | |
| SCHEMBL6207402 | 0.82 | AVPR1A (0.33) | BCHEACHEBACE1 | |
| SCHEMBL6207753 | 0.80 | MAP2K2 (0.34) | MAP2K2MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | claimed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | MAPK1, MAP3K1, MAPK3 | BCHE 3693/4885ACHE 2974/4885BACE1 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.